Bora Pharmaceuticals announced that its subsidiary, Upsher-Smith, has launched KYMBEE (Deflazacort Tablets), a branded generic for Duchenne Muscular Dystrophy (DMD) in patients aged 5 and older.

Patient Support and Market Expansion:

• Holistic Support: Chairman Bobby Sheng highlighted the "Promise of Support" program, which provides financial assistance and insurance navigation. Bora is partnering with Orsini, a leader in rare disease specialty pharmacy, to streamline drug access for caregivers.
• Pediatric Neurology: Another specialty drug, VIGAFYDE, continues to increase its U.S. market penetration. During "Epilepsy Awareness Month," the team engaged with the patient community at the Epilepsy Awareness & Education Expo in California to strengthen brand presence in the pediatric neurology space.
• Market Outlook: Research suggests the North American branded non-NME (New Molecular Entity) market will reach $867.2 billion by 2035 (CAGR: 8.47%). Bora’s sales model aims to build prescriber trust and patient loyalty in this high-value segment.

Resource: 保瑞兩大專科藥齊發力 搶攻美國罕病、癲癇醫療市場商機